Physician profile
Abigail Beck
NPI 1306245360
$2,372.26
in general payments reported to CMS, 2019-2025
22 companies · $360 in 2025
The $360 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $672 · 2022: $499 · 2023: $499 · 2024: $342 · 2025: $360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,201.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,201.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $915.13 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $269.39 | 2021-2024 | Mounjaro |
| Novo Nordisk INC | $219.72 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $190.46 | 2021-2025 | |
| Dexcom, INC. | $120.63 | 2021-2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $112.01 | 2021-2023 | |
| Pfizer INC. | $67.45 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $62.52 | 2024-2025 | Breztri, Airsupra |
| Merck Sharp & Dohme LLC | $57.05 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $55.29 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.94 | 2022-2024 | Jardiance |
| Amarin Pharma, INC. | $41.64 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $41.14 | 2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $38.26 | 2022 | |
| Lundbeck LLC | $20.14 | 2025 | Rexulti |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $19.68 | 2024 | Voquezna |
| Grifols USA, LLC | $19.02 | 2024 | Prolastin-C Liquid |
| Sanofi-Aventis U.S. LLC | $17.31 | 2025 | |
| Mylan Specialty L.P. | $16.96 | 2022 | |
| Corcept Therapeutics | $16.79 | 2025 | Korlym |
| Abbott Laboratories | $15.83 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.90 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abigail Beck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.